The mean progression-free Survival is >40 months with PRRT for Neuroendocrine Tumor Patients.

"Several researches and clinical trials have shown that Peptide Receptor Radionuclide Therapy (PRRT) is an exciting and effective advancement in the treatment of Neuroendocrine Tumors (NETs).
For more information on PRRT, do call us at +91 98111 27080,
or write to us at info@nuclearmedicinetherapy.in or visit https://nuclearmedicinetherapy.in/treatments/prrt"